-
Mashup Score: 0MAST Trial Finds Metformin Ineffective in Preventing Prostate Cancer Progression - Neil Fleshner - 9 hour(s) ago
Rashid Sayyid converses with Dr. Neil Fleshner about the outcomes of the MAST trial, which examined the effects of metformin on patients under active surveillance for prostate cancer. Despite promising preclinical evidence suggesting metformin’s potential benefits against prostate cancer, the trial results were unexpectedly negative, showing no significant advantage of metformin in preventing…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 4MAST Trial Finds Metformin Ineffective in Preventing Prostate Cancer Progression - Neil Fleshner - 2 month(s) ago
Rashid Sayyid converses with Dr. Neil Fleshner about the outcomes of the MAST trial, which examined the effects of metformin on patients under active surveillance for prostate cancer. Despite promising preclinical evidence suggesting metformin’s potential benefits against prostate cancer, the trial results were unexpectedly negative, showing no significant advantage of metformin in preventing…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 4MAST Trial Finds Metformin Ineffective in Preventing Prostate Cancer Progression - Neil Fleshner - 3 month(s) ago
Rashid Sayyid converses with Dr. Neil Fleshner about the outcomes of the MAST trial, which examined the effects of metformin on patients under active surveillance for prostate cancer. Despite promising preclinical evidence suggesting metformin’s potential benefits against prostate cancer, the trial results were unexpectedly negative, showing no significant advantage of metformin in preventing…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 4MAST Trial Finds Metformin Ineffective in Preventing Prostate Cancer Progression - Neil Fleshner - 4 month(s) ago
Rashid Sayyid converses with Dr. Neil Fleshner about the outcomes of the MAST trial, which examined the effects of metformin on patients under active surveillance for prostate cancer. Despite promising preclinical evidence suggesting metformin’s potential benefits against prostate cancer, the trial results were unexpectedly negative, showing no significant advantage of metformin in preventing…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
#WatchNow @FleshnerNeil and @RKSayyid discuss the surprising results of the #MAST trial, which found no significant benefits of #metformin in preventing #ProstateCancer progression during #ActiveSurveillance, in this conversation on UroToday > https://t.co/KZZUxlIUDz https://t.co/08JLFpsuLd